Daily Sepsis Research Analysis
Analyzed 18 papers and selected 3 impactful papers.
Summary
Three papers advance sepsis science across discovery-to-translation: a multi-omics framework prioritizes mitochondrial biomarkers for pathogen-specific stratification; preclinical data show β-nicotinamide mononucleotide preserves muscle strength via mitigating SIRT3-linked mitochondrial dysfunction; and a purified Curcumae Radix polysaccharide protects endothelium and dampens inflammation by inhibiting SPHK1 in sepsis models.
Research Themes
- Mitochondrial dysfunction and biomarker-driven sepsis stratification
- NAD+ augmentation to prevent ICU-acquired weakness after sepsis
- Endothelial protection via SPHK1 inhibition using plant-derived polysaccharides
Selected Articles
1. Integrative multi-omics and machine learning identify mitochondrial biomarkers for pathogen-specific sepsis stratification and translational prioritization.
By integrating sepsis GWAS, blood QTLs, and transcriptomes, the study prioritizes mitochondrial genes—especially those in inner membrane and matrix compartments—with consistent regulatory support. Machine learning models built from these features achieved an AUC of 0.91 in internal cross-validation, suggesting potential for pathogen-specific sepsis stratification pending external validation.
Impact: Provides a genetically anchored, multi-omics roadmap for sepsis biomarker discovery with strong internal predictive performance and pathogen-specific signals.
Clinical Implications: If externally validated, the mitochondrial gene panel could support early, pathogen-specific risk stratification and guide precision diagnostics or adjunctive therapies targeting mitochondrial pathways.
Key Findings
- Convergent genetic, epigenetic, and transcriptional evidence prioritized mitochondrial genes, with strongest signals in inner membrane and matrix compartments.
- Pathogen-associated expression patterns were observed across independent whole-blood transcriptomic cohorts (n=802 and n=163).
- A random forest model using mitochondrial features achieved an AUC of 0.91 under internal tenfold cross-validation.
Methodological Strengths
- Multi-omics integration of GWAS, molecular QTLs, and transcriptomics with compartment-aware mitochondrial annotation
- Model performance evaluated by internal tenfold cross-validation with independent cohorts for expression characterization
Limitations
- GWAS case numbers for pathogen-defined sepsis were modest, limiting power
- Predictive models were not externally validated; clinical utility remains unproven
Future Directions: Validate the biomarker panel in external, prospective cohorts and extend the framework to multi-omics layers such as metabolomics and single-cell datasets to refine pathogen-specific signatures.
BACKGROUND: Sepsis is a leading cause of critical illness and mortality, yet substantial heterogeneity limits risk stratification and biomarker translation. Mitochondrial dysfunction is widely implicated in sepsis, but genetically supported, multi-layer regulatory features and their clinical relevance remain incompletely characterized. METHODS: We integrated publicly available sepsis GWAS summary statistics (general sepsis: 1634 cases/454,714 controls; gram-positive sepsis: 168/456,180; gram-negative sepsis: 383/455,965) with blood-based molecular QTL resources (including GTEx v8 whole blood, n = 670) to prioritize mitochondrial genes and infer regulatory cascades. Independent whole-blood transcriptomic cohorts (the GAinS cohort, GSE65682, n = 802; GSE54514, n = 163) were used for clinical and pathogen-specific expression characterization. We developed machine learning models using mitochondrial gene features and evaluated performance by internal tenfold cross-validation. RESULTS: We identified mitochondrial genes with convergent genetic, epigenetic, and transcriptional regulatory evidence, showing stronger effects in inner membrane and matrix compartments. Transcriptomic analyses supported clinically relevant dysregulation and pathogen-associated patterns. In predictive modeling, aggregating mitochondrial gene features improved discrimination, with the best-performing random forest model achieving an AUC of 0.91 under internal cross-validation. These results require validation in independent external cohorts. CONCLUSIONS: This study provides a genetically supported, multi-omics framework linking compartment-specific mitochondrial dysregulation to sepsis heterogeneity and nominates candidate biomarkers for prioritization. The reported model performance reflects internal resampling and requires validation in independent clinical cohorts and future multi-omics profiling (including metabolomics) before translational implementation.
2. β-Nicotinamide mononucleotide preserves muscle strength in septic male mice.
In a cecal slurry sepsis model, muscle strength remained impaired at day 14 despite recovery of mass, paralleling persistent mitochondrial abnormalities and Sirt3 downregulation. β-NMN administration in the acute phase preserved mitochondrial morphology and muscle strength, and partially rescued bioenergetics in Sirt3-deficient myotubes, nominating NAD+ augmentation as a strategy against ICU-acquired weakness.
Impact: Links a mechanistic NAD+-SIRT3 axis to persistent post-sepsis muscle weakness and demonstrates a tractable intervention (β-NMN) that preserves strength in vivo.
Clinical Implications: While preclinical, findings support early NAD+ augmentation trials to prevent ICU-acquired weakness in sepsis survivors and suggest SIRT3-linked mitochondrial acetylation as a pharmacodynamic readout.
Key Findings
- Muscle strength remained impaired 14 days post-sepsis despite recovery of body weight and muscle mass, coincident with persistent mitochondrial abnormalities.
- Sirt3 expression was downregulated and mitochondrial protein lysine acetylation increased in septic muscle; several complex I subunits were detected in acetylated bands.
- β-NMN preserved mitochondrial morphology and muscle strength in vivo and partially rescued bioenergetics in Sirt3-deficient C2C12 myotubes.
Methodological Strengths
- Multi-tier approach combining in vivo sepsis model, transcriptomics, biochemistry, and cell-based knockdown assays
- Functional rescue experiments with β-NMN linking mechanism to intervention
Limitations
- Male mice only; sample size and randomization/blinding details not specified in the abstract
- Translational relevance requires dose-finding, safety, and efficacy in human sepsis
Future Directions: Conduct randomized preclinical studies across sexes and ages, define pharmacokinetics/pharmacodynamics of β-NMN in sepsis, and progress to early-phase clinical trials targeting ICU-acquired weakness.
Sepsis remains a leading cause of mortality and long-term disability, with survivors frequently developing intensive care unit-acquired weakness (ICU-AW) as part of post-intensive care syndrome. To identify a nutritional therapy for ICU-AW, we investigated the mechanisms underlying sepsis-induced skeletal muscle dysfunction using a cecal slurry-induced sepsis mouse model. Although body weight and skeletal muscle mass recovered 14 days after sepsis induction, muscle strength remained impaired, accompanied by persistent mitochondrial abnormalities. Transcriptomic analysis revealed that the pathways termed the 'sirtuin signaling pathway' and 'mitochondrial dysfunction' significantly enriched and Sirt3, a major mitochondrial nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylase, was downregulated. Biochemical analyses confirmed increased acetylated lysine of mitochondrial proteins in septic muscle tissue. Among these proteins, mass spectrometry detected several proteins in the acetylated band, including multiple complex I subunits. Whether these are direct SIRT3 targets remains to be determined. Knockdown of Sirt3 in C2C12 myotubes impaired mitochondrial respiration, whereas treatment with β-nicotinamide mononucleotide (β-NMN) partially rescued energy production. In vivo, acute-phase administration of β-NMN preserved mitochondrial morphology and skeletal muscle strength without altering muscle mass. These findings demonstrate that sepsis induces mitochondrial dysfunction and persistent muscle weakness associated with Sirt3 downregulation, and highlights β-NMN supplementation as a promising NAD⁺-targeted therapeutic strategy for mitigating ICU-AW.
3. Curcumae Radix polysaccharides alleviate sepsis in rats: Isolation and characterization of an active homogeneous polysaccharide.
CR polysaccharide and non-polysaccharide fractions reduced inflammation and coagulopathy in an LPS/carrageenan sepsis rat model by inhibiting SPHK1 signaling and protecting the endothelial barrier. A homogeneous glucan (CRP1-3, 5082 kDa, →4)-α-D-Glcp-(1→ backbone) was isolated and shown to exert potent anti-inflammatory and endothelial-protective effects in vitro.
Impact: Identifies a structurally defined polysaccharide that modulates SPHK1 signaling and endothelial integrity—two key axes in sepsis pathophysiology—expanding therapeutic leads from natural products.
Clinical Implications: While preclinical, the data highlight SPHK1 as a targetable pathway for endothelial stabilization in sepsis and propose CRP1-3-like polysaccharides as leads for adjunctive therapies.
Key Findings
- Both polysaccharide and non-polysaccharide fractions of Curcumae Radix showed anti-inflammatory and anticoagulant effects in LPS/carrageenan-induced sepsis in rats.
- Effects were mediated by inhibition of SPHK1 signaling, protecting vascular endothelial barrier and reducing liver and lung injury.
- A homogeneous glucan (CRP1-3; 5082 kDa; →4)-α-D-Glcp-(1→ backbone) was isolated and demonstrated strong anti-inflammatory and endothelial-protective activity in HUVEC assays.
Methodological Strengths
- Bioactivity-guided fractionation linking chemical structure to biological activity
- In vivo rat sepsis model complemented by endothelial cell assays for mechanism
Limitations
- LPS/carrageenan model may not recapitulate full clinical sepsis complexity
- Dose-response, pharmacokinetics, and safety data are not detailed in the abstract
Future Directions: Define pharmacology (PK/PD), optimize dosing and delivery, and test efficacy in polymicrobial sepsis models before advancing to translational studies.
Curcumae Radix (CR), a traditional Chinese herbal medicine, has shown potential in the treatment of sepsis, yet its active substances and mechanisms of action remain unclear. In this study, CR was separated into polysaccharide and non-polysaccharide fractions. Both fractions exhibited significant anti-inflammatory and anticoagulant effects in a rat model of sepsis induced by lipopolysaccharide (LPS) and carrageenan. These effects were mediated by sphingosine kinase 1 (SPHK1) signaling pathway inhibition, which protected the vascular endothelial barrier and consequently alleviated liver and lung tissue damage and mitigated sepsis symptoms. Additionally, bioactivity-guided fractionation in an LPS-induced human umbilical vein endothelial cell (HUVEC) injury model led to the isolation of a homogeneous polysaccharide, designated as CRP1-3 with a molecular weight of 5082 kDa. A physicochemical analysis and structural characterization revealed that CRP1-3 was a glucan with a backbone composed of →4)-α-D-Glcp-(1 → linkages. CRP1-3 demonstrated significant anti-inflammatory and endothelial-protective activity. These findings established that CRP is a substantially underestimated yet critical class of small-molecule active substances contributing to the anti-sepsis efficacy of CR.